Breakthrough treatments are bringing hope to countless patients suffering from disorders of the central nervous system (CNS).
At Allucent, we share your deep commitment to developing therapies to alleviate these conditions. Yet the challenges of CNS diseases bring associated challenges to conducting clinical trials. Cognitive impairment, memory loss, reduced movement and sensory capabilities – these create a high burden of disease on patients as well as the caregivers on whom many are dependent. Trial endpoints can be inadvertently influenced by patient expectations, placebo effects, and investigator biases. Highly specialized expertise, scrupulous quality control, and a patient-centric approach are paramount.
For more than 30 years, Allucent has been at the forefront of CNS clinical development projects worldwide, involving some 150 trials and more than 20 indications. Our expertise includes movement, demyelinating, and seizure disorders, as well as neurodegenerative and neurovascular diseases. We interact extensively with regulatory agencies in the U.S., Canada, and Europe to keep pace with the stipulations and advances in CNS trials and treatments.